Gabapentin
Product Images NDC 50090-5961

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-5961). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

An illustration showing the Cockcroft-Gault formula for estimating creatinine clearance (CLCr). The formula calculates CLCr using age, weight, and serum creatinine, with an adjustment factor for female patients.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph showing mean pain scores over 8 weeks comparing placebo and Gabapentin 3600 mg/day treatment. The x-axis represents weeks from baseline to week 8, separated into a 4-week dose titration period and a 4-week fixed dose period. The y-axis measures mean pain score on a scale from 0 to 10. The graph shows decreasing pain scores over time for Gabapentin compared to relatively stable scores for placebo.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph showing mean pain scores over seven weeks for placebo and two gabapentin dose groups (1800 mg/day and 2400 mg/day). The x-axis represents weeks, and the y-axis represents mean pain scores. The graph indicates pain score trends during a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

Bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) at different doses. Study 1 shows 12% responders for placebo and 29% for GBP 3600. Study 2 shows 14% responders for placebo and 32% and 34% for GBP 1800 and GBP 2400, respectively, with significance levels indicated (p < 0.01 and p < 0.001).*

FDA Label Image

Gabapentin-fig4.jpg (Gabapentin Fig4)

A scatter plot chart showing percentage difference versus daily dose (mg) for three different studies labeled as Study a, Study b, and Study c. Data points demonstrate how the percentage difference varies with increasing daily dose across the three studies with markers distinguished by color and labeled accordingly.*

FDA Label Image

Label Image (Lbl500905961)

Label for Gabapentin 300 mg capsules from A-S Medication Solutions. The label includes the product name, strength, labeler name, product NDC (50090-5961), lot and expiration details, storage instructions at 68 to 77 degrees Fahrenheit, and states the package contains 33 unit dose capsules. A QR code is also present on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.